Clinical trial
A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 28, 2005
- Completion date
- Not reported
- Enrollment
- 80 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.